- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07563777
100-Year Human Aging Study
100-Year Human Aging Study: Prospective Longitudinal Validation of Multi-System Health Measurements Against Mortality and Aging Outcomes
Studie Overzicht
Toestand
Conditie
- Hart-en vaatziekten
- Neoplasmata
- Sterfte
- Musculoskeletale aandoeningen
- Cognitieve disfunctie
- Metaboolsyndroom
- Dementie
- Kwetsbaarheid
- Veroudering
- Activiteiten van het dagelijks leven
- Handicap Fysiek
- Neuro-degeneratieve ziekte
- Goed ouder worden
- Sterfte door alle oorzaken
- Gezondheidsgerelateerde kwaliteit van leven
Interventie / Behandeling
Gedetailleerde beschrijving
All currently existing longevity measures are surrogate endpoints that have not been prospectively validated against actual mortality and aging outcomes. The 100-Year Human Aging Study is a prospective, pragmatic, observational trial that addresses this gap by enrolling participants in comprehensive clinical screening and following them longitudinally until death to determine which measurements - alone and in combination - are predictive of mortality, serious disease, and functional disability.
The study prioritizes dynamic measurements: the physiological, cognitive, social, and environmental capacities that change with aging and are most likely to carry predictive signal for mortality and functional outcomes. These include cardiorespiratory fitness (cardiopulmonary exercise testing with ventilatory threshold analysis), strength (grip, explosive power, functional movement), mobility and balance, neurocognitive performance, sensory function (vision, hearing, smell, light touch), and metabolic function (oral glucose tolerance, continuous glucose monitoring), in addition to other testing. Structural and imaging assessments include body composition and bone mineral density by DEXA, echocardiography, resting and stress electrocardiography, spirometry, retinal fundus photography, and vascular ultrasound. Laboratory measures are drawn on-site and processed through a CLIA-certified reference laboratory. Complete medical, surgical, family, social, occupational, and environmental histories are obtained at each visit.
Participation ranges from single-service visits - including standalone DEXA, cardiopulmonary exercise testing, laboratory panel testing, and sleep studies - to the full two-visit comprehensive screening battery. All participation pathways contribute clinical data to the longitudinal mortality and aging outcomes linkage framework regardless of service level. Participants are encouraged to return for repeat testing to build longitudinal health trajectories across the lifespan.
At enrollment and across longitudinal follow-up, the study platform generates individualized investigational constructs including biological age estimate, predicted death age, and predicted cause of death profile. These are explicitly investigational hypotheses, not validated clinical standards. Their predictive validity relative to actual mortality, aging outcomes, and functional disability is a central scientific question this study is designed to answer, both for individual measures and for composite multi-system models.
All data are archived in their highest-dimensional raw form to preserve the ability to apply future analytical methods retroactively. Participants are followed with periodic contact and offered repeat screening throughout the lifespan. Longitudinal outcomes ascertainment includes all-cause mortality, cause-specific mortality, incident serious health events, chronic disease diagnosis, functional independence, disability status, and health behavior change.
Study sites and participation pathways. The 100-Year Human Aging Study is conducted across all Longevity Metrics participation pathways, current and future: the Boulder Human Performance Lab (fixed flagship laboratory); mobile screening units including the Health Ahead Bus; any additional fixed or mobile Longevity Metrics laboratory established during the study period; and an online participation pathway through which participants enroll and contribute structured data without in-person screening. All pathways operate under a single protocol with identical procedures, data management, informed consent, and safety standards.
This study is one of four that compound into one system. The Human Observatory Study (NCT07646782) validates sociodemographic and environmental data against the same outcomes, and receives each model's geographic residuals. The Health Ahead Comparative Effectiveness Study (NCT07669168) moves the screening toward increasing automation and mobility while maintaining quality. The Longevity Metrics AI/ML Development Study (NCT pending approval) builds the models that make automation, prediction, and broad utilization possible. This study supplies the clinical data and validates what it means for health, disease, disability, and death.
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studiecontact
- Naam: William E Brandenburg, MD
- Telefoonnummer: 3035010016
- E-mail: info@longevitymetrics.org
Studie Locaties
-
-
Colorado
-
Boulder, Colorado, Verenigde Staten, 80301
- Werving
- Longevity Metrics
-
Contact:
- William E Brandenburg, MD
- Telefoonnummer: 3035010016
- E-mail: info@longevitymetrics.org
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:
- Age 18 years or older
- Willing and able to provide written informed consent, or enrollment with consent of a legally authorized representative
- Willing to participate in longitudinal follow-up
Exclusion Criteria:
- Age under 18 years
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
All-Cause Mortality
Tijdsspanne: From enrollment until death, assessed periodically, up to 100 years
|
Vital status ascertained through longitudinal follow-up contact, mortality record linkage, and health data network linkage using probabilistic matching on name, date of birth, and address history.
|
From enrollment until death, assessed periodically, up to 100 years
|
|
Cause-Specific Mortality
Tijdsspanne: From enrollment until death, assessed periodically, up to 100 years
|
Cause of death ascertained via death certificate and mortality record linkage.
|
From enrollment until death, assessed periodically, up to 100 years
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Cause-Specific Mortality Prediction Accuracy
Tijdsspanne: From enrollment until death, assessed periodically, up to 100 years
|
Concordance between predicted cause of death profile generated at enrollment and actual cause of death ascertained at follow-up.
|
From enrollment until death, assessed periodically, up to 100 years
|
|
Incident Serious Adverse Health Events
Tijdsspanne: Periodically from enrollment until death, up to 100 years
|
New diagnosis of myocardial infarction, stroke, cancer, dementia, heart failure, atrial fibrillation, sepsis, venous thromboembolism, COPD, chronic hypoxia, or major fracture ascertained via periodic follow-up contact and health data network linkage.
|
Periodically from enrollment until death, up to 100 years
|
|
Incident Chronic Disease
Tijdsspanne: Periodically from enrollment until death, up to 100 years
|
New diagnosis of type 2 diabetes, hypertension, COPD, chronic kidney disease, metabolic syndrome, or osteoporosis ascertained via self-report and health data network linkage.
|
Periodically from enrollment until death, up to 100 years
|
|
Functional Independence and Disability Status
Tijdsspanne: Periodically from enrollment until death, up to 100 years
|
Activities of daily living, instrumental activities of daily living, and self-reported disability status ascertained via periodic health survey using validated open-source instruments.
Higher composite scores indicate greater functional independence.
Specific instruments will be selected prior to first follow-up contact and documented in the statistical analysis plan.
|
Periodically from enrollment until death, up to 100 years
|
|
Biological Age Estimate Prediction Accuracy
Tijdsspanne: Periodically from enrollment until death, up to 100 years
|
Concordance between investigational biological age estimate and actual mortality outcomes at longitudinal follow-up.
|
Periodically from enrollment until death, up to 100 years
|
|
Health Behavior Change: Composite Self-Report and Repeat Screening Index
Tijdsspanne: Periodically from enrollment until death, up to 100 years
|
Health behavior change assessed through two complementary measures aggregated into a single index: validated composite self-report survey administered at periodic follow-up, and change in pre-specified clinical measurements at repeat screening.
Improvement in objective clinical measurements (cardiorespiratory fitness, body composition, metabolic biomarkers, and related parameters) serves as the primary behavioral activation signal.
Self-report domains including health behaviors and preventive care utilization provide supporting context.
Both are combined into a single participant-level health activation index.
Higher scores indicate greater engagement with health-promoting behaviors and measurable clinical improvement.
|
Periodically from enrollment until death, up to 100 years
|
|
Multi-System Predictor Modeling: Predictive Performance
Tijdsspanne: Periodically from enrollment until death, up to 100 years
|
Performance of a unified multi-domain measurement framework in predicting all-cause mortality and incident serious disease.
The framework integrates clinical, biological, behavioral, social, occupational, and environmental data into a single composite model.
Performance is reported for the full composite model, with pre-specified secondary reporting for individual predictor domains and domain combinations to identify which inputs are independently predictive, which are redundant, and which combinations provide additive or synergistic predictive value.
Metrics are specified in the statistical analysis plan.
|
Periodically from enrollment until death, up to 100 years
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: William E Brandenburg, MD, Longevity Metrics, Inc.
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
- Lichaamssamenstelling
- Levensduur
- Volksgezondheid
- Preventieve geneeskunde
- Functionele achteruitgang
- Gezondheidsspanne
- Cardiopulmonale inspanningstesten
- Biologische veroudering
- Preventieve screening
- Menselijke prestaties
- Levensverwachting
- Sterftevoorspelling
- Surrogate Endpoint Validation
- Longitudinal Cohort
- Biomarker Validation
- Centenarian
Aanvullende relevante MeSH-voorwaarden
- Hersenziekten
- Ziekten van het centrale zenuwstelsel
- Ziekten van het zenuwstelsel
- Psychische aandoening
- Pathologische processen
- Metabole ziekten
- Neurocognitieve stoornissen
- Glucosemetabolismestoornissen
- Cognitieve stoornissen
- Insuline-resistentie
- Hyperinsulinisme
- Pathologische aandoeningen, tekenen en symptomen
- Voedings- en stofwisselingsziekten
- Kwetsbaarheid
- Neoplasmata
- Cognitieve disfunctie
- Hart-en vaatziekten
- Metaboolsyndroom
- Musculoskeletale aandoeningen
- Dementie
Andere studie-ID-nummers
- 100Year
- IORG0012336 (Andere identificatie: OHRP)
- IRB00014601 (Andere identificatie: OHRP)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .